Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 6/20 | 0.40 |
| ▸ | LTA4H | P09960 | 7/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13918480 | 0.92 | CYSLTR2 (0.46) | CYSLTR2PPARGLTA4HL3MBTL1PPARD | |
| SCHEMBL4517384 | 0.92 | CYSLTR2 (0.46) | CYSLTR2PPARGLTA4HPOLBCASP6 | |
| SCHEMBL4526325 | 0.87 | CYSLTR2 (0.49) | CYSLTR2PPARGLTA4HPOLBCASP6 | |
| SCHEMBL13918373 | 0.85 | CYSLTR2 (0.51) | CYSLTR2LTA4H | |
| SCHEMBL4508081 | 0.84 | CYSLTR2 (0.40) | CYSLTR2PPARGMEN1KMT2A | |
| SCHEMBL4532981 | 0.84 | CYSLTR2 (0.55) | CYSLTR2POLBCASP6 | |
| SCHEMBL4517382 | 0.83 | TSHR (0.41) | CYSLTR2POLBCASP6TDP1PPARD | |
| SCHEMBL13918518 | 0.83 | TSHR (0.56) | CYSLTR2MEN1KMT2A | |
| SCHEMBL4510798 | 0.82 | CYSLTR2 (0.53) | CYSLTR2PPARGPOLBCASP6TDP1 | |
| SCHEMBL13918434 | 0.80 | HPGD (0.40) | CYSLTR2LTA4HMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498460-B2 | Isophthalic acid derivatives | BAYER HEALTHCARE AG (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7498460-B2 | Isophthalic acid derivatives | BAYER HEALTHCARE AG (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7498460-B2 | Isophthalic acid derivatives | BAYER HEALTHCARE AG (DE) | 2009-03-03 | — | — | US | disclosed |
| EP-1572628-B1 | ISOPHTALIC ACID DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2007-07-25 | — | — | EP | disclosed |
| US-20060154912-A1 | Isophtalic acid derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154912-A1 | Isophtalic acid derivatives | VHL, FABP3, CPT1A | CYSLTR2 1426/4885PPARG 194/4885LTA4H 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.